四川医学2012，Vol.33Issue(4)：632-633,2.
β受体拮抗剂在心血管疾病的COPD患者中疗效评估
The efficacy assessment of β blockers in COPD patients with cardiovascular disease.
杨燕 1任云芬 1徐大敏 1程德忠 1刘继东 1程晓伟 1王浩凌 1李淑梅 1刘莹1
作者信息
- 1. 攀枝花市中心医院呼吸内科,四川攀枝花617000
- 折叠
摘要
Abstract
Objective To study effect of β blockers in patients with COPD and cardiovascular disease. Methods Patients with COPD complicated by cardiovascular disease was divided into five groups; ICS, ICS + LABA + TIO, ICS + LABA + TIO + BB, BB, Placebo group, retrospective analysis influence of (5 blockers on lung function, oxygen saturation and mortality. Results BB treatment group, compared with the ICS, ICS + LABA + TIO group, had no significant decrease about FEV1, a statistically significant difference (t =7. 069, P<0. 05) ; no significant difference of SpO2(f =3. 076, P>0. 05) ; β blockers treatment group could effectively reduce the mortality, overall mortality rate was 18% (t= 16. 87 , P < 0. 05 ) . Conclusion Concurrent βblockers did not reduce FEV1 in patients with COPD with cardiovascular disease, could reduce the mortality rate.β blockers; lung function; COPD关键词
β受体拮抗剂/肺功能/慢性阻塞性肺部疾病Key words
β blockers/ lung function/ COPD分类
医药卫生引用本文复制引用
杨燕,任云芬,徐大敏,程德忠,刘继东,程晓伟,王浩凌,李淑梅,刘莹..β受体拮抗剂在心血管疾病的COPD患者中疗效评估[J].四川医学,2012,33(4):632-633,2.
